Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Apr. 27, 2025	Apr. 28, 2024	Jan. 26, 2025
Cash flows from operating activities:
Net income (loss)	$ 19,345	$ (23,159)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	10,190	10,504
Amortization of right-of-use assets	1,346	1,431
Investment impairments and credit loss reserves, net	0	1,109
Accretion of deferred financing costs	1,254	2,379
Write-off of deferred financing costs	152	0
Interest rate swap termination	14	0
Deferred income taxes	2,411	(884)
Share-based compensation	6,835	15,234
Loss on disposition of business operations and assets	26	64
Equity method income	(1,046)	(50)
Gain from sale of investments	0	(277)
Corporate-owned life insurance, net	655	695
Changes in assets and liabilities:
Accounts receivable, net	(3,107)	(19,613)
Inventories	(6,627)	(3,632)
Other assets	2,281	13,610
Accounts payable	9,805	19,053
Accrued liabilities	(15,444)	(14,260)
Other liabilities	(266)	(2,293)
Net cash provided by (used in) operating activities	27,824	(89)
Cash flows from investing activities:
Purchase of property, plant and equipment	(1,650)	(1,334)
Proceeds from sale of investments	536	2,650
Purchase of intangibles	(529)	(1,326)
Proceeds from corporate-owned life insurance	0	1,801
Premiums paid for corporate-owned life insurance	(3,428)	0
Net cash (used in) provided by investing activities	(5,071)	1,791
Cash flows from financing activities:
Payments of term loans	(10,000)	0	$ (441,400)
Deferred financing costs	(492)	(824)
Payments for employee share-based compensation payroll taxes	(8,901)	(2,425)
Proceeds from exercise of stock options	32	235
Distributions to noncontrolling interest	0	(184)
Net cash used in financing activities	(19,361)	(3,198)
Effect of foreign exchange rate changes on cash and cash equivalents	1,339	(312)
Net increase (decrease) in cash and cash equivalents	4,731	(1,808)
Cash and cash equivalents at beginning of period	151,743	128,585	128,585
Cash and cash equivalents at end of period	156,474	126,777	$ 151,743
Supplemental disclosure of cash flow information:
Interest paid	3,526	17,147
Income taxes paid	1,335	2,769
Non-cash investing and financing activities:
Accounts payable related to capital expenditures	247	331
Accrued deferred financing costs	72	0
Accrued purchases of intangibles	$ 5,130	$ 0